Tri Locum Partners LP Fate Therapeutics Inc Transaction History

Tri Locum Partners LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$17.78 - $42.39 $3.38 Million - $8.07 Million	-190,345 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $1.43 Million - $2.91 Million	48,313 Added 34.02%	190,345 $7.38 Million
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $6.79 Million - $9.14 Million	142,032 New	142,032 $8.31 Million

183

123M

15K

14K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $230M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Tri Locum Partners LP, based on Form 13F filings with the SEC.

Stay updated on Tri Locum Partners LP with notifications on news.